Non-contrast diffusion MRI holds great potential to screen women for breast cancer. Restriction spectrum imaging (RSI) is an advanced diffusion-weighted imaging (DWI) technique that reflects the high nuclear to cytoplasm ratio observed in cancer cells. This abstract explores RSI as a technique to non-invasively identify malignant from benign masses on non-contrast MRI by measuring RSI cellularity index (RSI-CI). Biopsy-proven malignant masses demonstrate high cellularity index compared to benign lesions. In this pilot study, RSI differentiates malignant from benign masses without contrast imaging, and could prove useful as a screening tool.